All Stories

  1. A step by step guide to analysing sets of n-of-1 trials using simple explanations.
  2. Statistical issues in a study of the effect of milk on growth of schoolchildren
  3. Conditions for success and margins of error: Estimation in clinical trials
  4. Heterogeneity in meta-analysis
  5. On the relevance of prognostic information for clinical trials: A theoretical quantification
  6. 1000 Patients are not Necessary for Balance in a Randomised Trial
  7. The design and analysis of COVID vaccine trials.
  8. Problems with the two-stage analysis of cross-over trials
  9. Using Historical Controls in Oncology
  10. Cluster trials are a closer analogue to studies using historical controls than parallel group trials
  11. A scientific biography of John Nelder
  12. Modelling treatment main effects as random in network meta-analyses with many similar treatments
  13. Naive statistics lead to misunderstandings about personalised medicine
  14. Childhood asthma exacerbations and ADRB2 polymorphism: Caution is needed
  15. Evidence against precision medicine?
  16. The origin of the data that Student used to illustrate his t-test in his famous paper of 1908.
  17. Sample sizes needed to attain chosen power when planning groups of n-of-1 trials
  18. A partial if not impartial defence of P-values
  19. Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice
  20. Variation in N-of-1 Trials
  21. Why the scope for personalizing medicine may be less than you think
  22. Progression-seeking bias and rational optimism in research and development
  23. Individual response to exercise training - a statistical perspective
  24. Pharmaceutical Industry, Statistics in: Including Two Examples
  25. Justice, Rawlsian Theory of
  26. Pharma industry productivity is not so great after all
  27. Meta-analysis of sequential trials
  28. Crossover Designs
  29. Statistics in Medicine
  30. Baseline Adjustment in Longitudinal Studies
  31. Caution needed in using Lee's checks for relative risks.
  32. Designing proof of concept trials for treatment of pain
  33. Paediatric legislation may be bad for children
  34. What does 'random effect' mean?
  35. Sources of variation in observed response in trials in pain
  36. Various varying variances
  37. Review of Bad Pharma
  38. Predicting patient recruitment
  39. Contribution to Bob O'Neil Festschrift
  40. Errors of conditional probability
  41. A reply to Chalmers and Dickersin
  42. A note on randomization
  43. Crossover design
  44. P-values explained
  45. Myths of randomisation
  46. When understood properly the data show that editors have a bias in favour of positive results
  47. Editors are biased against negative studies
  48. Tea for three
  49. It works in practice, but does it work in theory?
  50. Dealing with observations below the limit of quantitation
  51. Lecture at the 2011 clinical trials conference in Bristol
  52. Simplicity versus complexity in modelling
  53. Chapter 3 of the book Simplicity Complexity and Modelling
  54. Chapter 2 of Simplicity, Complexity and Modelling
  55. Model selection and other matters
  56. Chapter 1 of Simplicity, Complexity and Modelling
  57. Review of Fleiss, statistical methods for rates and proportions
  58. Francis Galton and regression to the mean
  59. SAS Macros for meta-analysis
  60. Randomisation does not cure all problems but it is still valuable
  61. Cross-over trials in infertility
  62. RA Fisher and significance
  63. PK modellers and statisticians should collaborate
  64. Design and Analysis of Cross-over Trials
  65. Understanding P-values
  66. Efficiency of two approaches to dynamic balancing in clinical trials
  67. Some remarks concerning meta-analysis
  68. Commentary on Rosemary' Baily's paper on dose escalation
  69. Authors' Rejoinder to Commentaries on ‘Measurement in clinical trials: A neglected issue for statisticians?’
  70. Measurement in Clinical Trials
  71. Comment on Robert et al
  72. Double counting in meta-analysis and related problems
  73. Invited comment on a paper by Ioannidis
  74. Correction
  75. Dawid's selection paradox
  76. Editorial/Letters
  77. Two trials illustrating points about randomisation
  78. A dram of data is worth a pint of pontification
  79. Faculty Opinions recommendation of Are flexible designs sound?
  80. When and how to use the t-test
  81. The history of the t-test
  82. Budesonide and Formoterol in Combination: an Incomplete Blocks Cross-over
  83. Authors' Reply
  84. A comment on an article by Andrew Gelman
  85. Statistical Issues
  86. The propensity score is problematic
  87. Multiple endpoints plus Bonferroni may gain power
  88. Safety first?
  89. Drawbacks to Noninteger Scoring for Ordered Categorical Data
  90. Faculty Opinions recommendation of Semiparametric analysis of case series data.
  91. Cross-over trials in Statistics in Medicine : the first ‘25’ years
  92. Sharp tongues and bitter pills
  93. Lord's paradox and ANCOVA
  94. Prior distributions for random effect meta-analysis
  95. Epigenetic analysis must allow for dependence of observations
  96. An Early “Atkins' Diet”: RA Fisher Analyses a Medical “Experiment”
  97. Faculty Opinions recommendation of Surrogate endpoints in clinical trials: definition and operational criteria.
  98. Faculty Opinions recommendation of A likelihood approach to meta-analysis with random effects.
  99. Medicine, Statistics in
  100. Rawlsian
  101. Statistics in Medicine
  102. Errors in understanding cross-over trials
  103. Bitter Pills and Puffed Trials
  104. Bernoulli Family
  105. Comment
  106. Sizing up the world
  107. Crossover designs
  108. Pharmaceutical Industry, Statistics In
  109. Baseline Adjustment in Longitudinal Studies
  110. Some comments on therapeutic equivalence
  111. Authors' Reply
  112. Modelling may save lives and money
  113. Controversies concerning randomization and additivity in clinical trials
  114. Bioequivalence for beginners
  115. Medicine, Statistics in
  116. Justice, Rawlsian Theory of
  117. Tribute to John Nelder on his 80th birthday
  118. The analysis of the AB/BA cross‐over trial in the medical literature
  119. Carry‐over in cross‐over trials in bioequivalence: theoretical concerns and empirical evidence
  120. Preface
  121. Chance, risk and health
  122. Circling the square
  123. Chapter 2 of Dicing with Death
  124. Trials of life
  125. Of dice and men
  126. Time's tables
  127. Sex and the single patient
  128. A hale view of pills
  129. Meta-analysis and related matters
  130. The things that bug us
  131. The empire of the sum
  132. The law is a ass
  133. Preface
  134. Permissions
  135. Dichotomising continuous outcomes is bad
  136. Patents, pharmaceuticals & statistics
  137. P-Values
  138. Crossover Design
  139. Examples of option values in drug development
  140. John Nelder: life and work
  141. Lost opportunities for statistics
  142. Caution is needed in applying nonparametric ANCOVA
  143. Replication probabilities of P-values are irrelevant
  144. A practical text on designing and analysing cross-over trials
  145. Pharma scientists should appear more often on publications
  146. The Unpleasant Placebo?
  147. Screening for breast cancer with mammography
  148. Problems in personalising medicine
  149. Controversies in bioequivalance
  150. The p-value and its critics
  151. Letters to the Editor
  152. Statistical Issues in Clinical Trials in Neurology
  153. Linear models versus meta-analysis in analysing multi-centre trials
  154. Consensus and Controversy in Pharmaceutical Statistics
  155. Letters to the editor
  156. The summary measures approach for clinical trials
  157. Screening mammography re-evaluated
  158. A Comment on Optimal Allocations for Bioequivalence Studies
  159. Preface
  160. Realistic models for carry-over
  161. Robust and realistic approaches to carry‐over
  162. Correspondence
  163. Some controversies in planning and analysing multi‐centre trials
  164. Individual bioequivalance is unnecessary
  165. Bayesian and frequentist approaches to the cross-over trial
  166. Uncertainty can be valuable in drug development
  167. Why you should not use the two-stage analysis of AB/BA cross-overs
  168. On wisdom after the event
  169. P100 Individualizing patient therapy
  170. 35 How to perform the two-stage analysis of cross-over trials if you can't be persuaded not to
  171. A violation of informed consent
  172. Pharmaceutical Project Prioritization
  173. How to rank drug development projects
  174. A Comment on Interim Analyses in Crossover Trials
  175. Controversies in clinical trials
  176. In defence of analysis of covariance: A reply to Chambless and Roeback
  177. Use baseline covariates rather than testing them
  178. Cushny, Peebles & Student
  179. Randomisation in clinical trials
  180. A Bayesian paradox of confirmation
  181. Regression toward the mean in 2 × 2 crossover designs with baseline measurements
  182. Suspended judgment n-of-1 trials
  183. Baseline distribution and conditional size
  184. Letters to the editor
  185. A Popperian view of clinical trials
  186. Competence, control, confirmation and refutation
  187. Review of Howson and Urbach
  188. Regression is not always to the mode
  189. Covariance analysis in generalized linear measurement error models
  190. Combining Outcome Measures: Statistical Power Is Irrelevant
  191. Testing for covariate imbalance does not deal with it
  192. Analysis of an epidemic of Q Fever
  193. Sober view of AIDS
  194. Estimating regression to the mean